Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: A randomised double-blind placebo-controlled trial

Thorax

Volumn 68, Issue 4, 2013, Pages 338-343

  Edwards, Llifon ^a,b   Shirtcliffe, Philippa ^a,b   Wadsworth, Kirsten ^a,c   Healy, Bridget ^a,b   Jefferies, Sarah ^a,b   Weatherall, Mark ^b,d   Beasley, Richard ^a,b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c Hutt Valley District Health Board   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; MAGNESIUM SULFATE; PLACEBO; SALBUTAMOL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW ZEALAND; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 84875229234     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202225     Document Type: Article

References (37)

1. Fawcett W, Haxby E, Male D. Magnesium: physiology and pharmacology. Br J Anaesth 1999;83:302-20.
2. Herroeder S, Schonherr M, De Hert S, et al. Magnesium essentials for anesthiologists. Anesthesiology 2011;114:971-93.
3. Spivey W, Skobeloff E, Levin R. Effect of magnesium chloride on rabbit bronchial smooth muscle. Ann Emerg Med 1990;19:1107-12. (Pubitemid 20365199)
4. del Castillo J, Engbaek L. The nature of the neuromuscular block produced by magnesium. J Physiol 1954;124:370-84.
5. Rosello H, Pla J. Sulfato de magnesio en la crisis de asma. Presna Med Argent 1936;23:1677-80.
6. Silverman R, Osborne H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma. Chest 2002;122:489-97.
7. Bloch H, Silverman R, Mancherje N, et al. Intravenous magnesium sulphate as an adjunct in the treatment of acute asthma. Chest 1995;107:1576-81.
8. Skobeloff EM, Spivey WH, McNamara RM, et al. Intravenous magnesium sulphate for the treatment of acute asthma in the emergency department. JAMA 1989;262:1210-13. (Pubitemid 19206698)
9. Schenk P, Vonbank K, Schnack B, et al. Intravenous magnesium sulphate for bronchial hyperreactivity: a randomized, controlled, double-blind study. Clin Pharmacol Ther 2001;69:365-71. (Pubitemid 32477078)
10. Rowe B, Bretzlaff J, Bourdon C, et al. Magnesium sulphate for treating exacerbations of asthma in the emergency department. Cochrane Database Syst Rev 2006;3:1-26.
11. Mangat H, D'Souza G, Jacob M. Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: a clinical trial. Eur Respir J 1998;12:341-4. (Pubitemid 28389526)
12. Nannini L, Pendino J, Corna R, et al. Magnesium sulphate as a vehicle for nebulised salbutamol in acute asthma. Am J Med 2000;108:193-7. (Pubitemid 30100610)
13. Hughes R, Goldkorn A, Masoli M, et al. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in the treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet 2003;361:2114-17. (Pubitemid 36782255)
14. Blitz M, Blitz S, Beasley R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2006;3:1-28.
15. Hogg J, Mulrennan S, Everett C, et al. A single centre double-blind placebo-controlled pilot study into the use of intravenous magnesium sulphate for the treatment of acute exacerbation of COPD (abstract). Eur Respir J 2004; 24(Suppl 48):343s.
16. Skorodin M, Tenholder M, Yetter B, et al. Magnesium sulphate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 1995;155:496-500.
17. Do Amaral AF, Rodrigues-Junior AL, Filho JT, et al. Effects of acute magnesium loading on pulmonary function of stable COPD patients. Med Sci Monit 2008;14:CR524-9.
18. Tagaya E, Tamaoki J, Kawatani K, et al. The effect of isotonic nebulized magnesium sulfate on pulmonary function in moderate to severe COPD. Am J Respir Crit Care Med 2004;169:A521.
19. Gonzalez J Abreu, Garcia C Hernandez, Gonzalez P Abreu, et al. Effect of magnesium sulphate on chronic obstructive pulmonary disease exacerbations requiring hospitalization: a randomised placebo-controlled trial (abstract). Arch Bronconeumol 2006;42:384-7.
20. Nouira S, Bouida W, Grissa M, et al. Magnesium sulphate versus ipratropium bromide in chronic obstructive pulmonary disease exacerabation: a randomised trial. Am J Ther Published Online First: 8 Mar 2012. doi:10.1097/MJT.0b013e3182459a8e
21. Niewoehner D, Collins D, Erbland M. Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1201-5. (Pubitemid 30243830)
22. Tashkin D, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.
23. Stoller J. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;346:988-94. (Pubitemid 34983250)
24. Global Strategy for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org (accessed Dec 2011).
25. British Thoracic Society (BTS). BTS guidelines for the management of COPD. Thorax 1997;52:S1-28.
26. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guidelines for the management of COPD in adult sin primary and secondary care. Thorax 2004;59:S1-232.
27. Teale C, Morrison J, Page R, et al. Dose response to inhaled salbutamol in chronic obstructive airways disease. Postgrad Med J 1991;67:754-6.
28. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994;105:1411-19.
29. Dorinsky P, Resiner C, Ferguson G, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999;115:966-71. (Pubitemid 29193662)
30. Beasley R, Rafferty P, Holgate S. Adverse reactions to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol 1988;25:283-7.
31. Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet 2009;374:670-2.
32. Diaz-Guzman E, Mannino D. Airway obstructive diseases in older adults: from detection to treatment. J Allergy Clin Immunol 2010;126:702-9.
33. Rolla G, Bucca C, Bugiani M, et al. Hypomagnesemia in chronic obstructive lung disease: effect of therapy. Magnesium Trace Elem 1990;9:132-6. (Pubitemid 20328412)
34. Bhatt S, Khandelwal P, Nanda S, et al. Serum magnesium is an independent predictor of frequent readmissions due to acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2008;102:999-1003.
35. Azziz H, Blamoun A, Shubair M, et al. Serum magnesium levels and acute exacerbations of chronic obstructive pulmonary disease: a retrospective study. Ann Clin Lab Sci 2005;35:423-7. (Pubitemid 41579573)
36. Molloy D, Dhingra S, Solven F, et al. Hypomagnesemia and respiratory muscle power. Am Rev Respir Dis 1984;129:497-8. (Pubitemid 14197275)
37. Corradi M, Acampa O, Goldoni M, et al. Metallic elements in exhaled breath condensate and serum of patients with exacerbation of chronic obstructive pulmonary disease. Metallomics 2009;1:339-45.